GCTK · XBRL financial data

Glucotrack financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (GCTK's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	1,693	1,742*	2,148	3,589	2,063	1,699*	1,871	3,150	3,165	1,627*	2,132	2,016
General and administrative	531	553*	733	802	1,063	2,057*	1,499	1,464	1,024	2,290*	2,071	1,384
Total operating expenses	2,224	2,417*	2,951	4,491	3,251	3,854*	3,498	4,796	4,309	3,487*	4,203	3,400
Operating income (loss)	(2,224)	(2,417)*	(2,951)	(4,491)	(3,251)	(3,854)*	(3,498)	(4,796)	(4,309)	(3,487)*	(4,203)	(3,400)
Interest expense	—	—	—	—	5	39*	—	—	—	—	—	—
Other income (expense)	—	—	—	—	12	2*	4	(96)	136	(18)*	(132)	(414)
Net income (loss)	(2,223)	(2,412)*	(2,927)	(4,489)	(5,087)	(10,094)*	(6,833)	(4,756)	(4,171)	(3,628)*	(4,334)	(3,814)
Earnings per share, basic USD per share	(0.10)	—	(0.12)	0.82	(0.91)	—	(0.67)	9.62	4.64	—	2.65	0.76
Earnings per share, diluted USD per share	(0.10)	—	(0.12)	0.82	(0.91)	—	(0.67)	9.62	4.64	—	2.65	0.76
Weighted average shares, basic thousands of shares	22,969	22,902*	24,960	5,476	5,595	—	10,161	495	899	—	1,638	5,009
Weighted average shares, diluted thousands of shares	22,969	22,902*	24,960	5,476	5,595	—	10,161	495	899	—	1,638	5,009

† Share count changed about 1/5 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/32 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (GCTK's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	6,888	4,492	1,497	159	346	5,617	9,100	9,555	7,869	7,383	3,929	1,124
Total current assets	7,169	4,868	1,937	442	642	5,768	9,455	10,077	8,106	7,667	4,214	1,381
Property and equipment, net	17	27	82	86	109	95	94	87	144	138	116	95
Right-of-use asset	—	—	77	71	65	59	53	46	40	33	26	19
Total assets	7,195	4,905	2,106	608	826	5,932	9,612	10,210	8,290	7,838	4,356	1,495
Accounts payable	1,249	839	1,014	2,736	1,857	992	1,612	2,644	1,709	1,317	1,299	1,116
Total current liabilities	1,454	1,512	1,482	3,660	4,611	1,275	1,950	3,085	5,297	4,773	4,975	2,988
Lease liability, non-current	—	—	53	46	40	33	26	19	12	5	—	—
Total liabilities	1,638	1,708	1,730	3,897	4,848	18,932	2,354	3,330	5,539	5,010	5,207	3,236
Accumulated deficit	(107,441)	(109,853)	(112,780)	(117,269)	(122,356)	(132,450)	(139,283)	(144,039)	(148,210)	(151,838)	(156,172)	(159,986)
Total stockholders' equity	5,557	3,197	376	(3,289)	(4,022)	(13,000)	7,258	6,880	2,751	2,828	(851)	(1,741)
Total liabilities and equity	7,195	4,905	2,106	608	826	5,932	9,612	10,210	8,290	7,838	4,356	1,495
Common shares outstanding (cover page) thousands of shares	20,892	26,756	27,393	5,478	5,772	25,586	28,643	899	911	1,944	6,259	10,579

† Share count changed about 1/5 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/32 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (GCTK's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,223)	(2,412)*	(2,927)	(4,489)	(5,087)	(10,094)*	(6,833)	(4,756)	(4,171)	(3,628)*	(4,334)	(3,814)
Stock-based compensation	31*	21*	22	206*	11*	(66)*	40	40*	41*	90*	61	59*
Depreciation and amortization	—	—	4	—	—	—	—	—	—	—	—	—
Net cash from operating activities	(1,880)*	(2,411)*	(2,942)	(1,907)*	(4,142)*	(3,499)*	(2,939)	(3,744)*	(4,621)*	(3,936)*	(4,048)	(3,616)*
Purchases of property and equipment	—	—	59	12*	33*	0*	9	0*	67*	20*	—	—
Net cash from investing activities	—	—	(59)	(12)*	(33)*	0*	(9)	0*	(67)*	(20)*	—	—
Net cash from financing activities	0*	0*	—	—	4,380*	8,783*	6,395	4,160*	2,994*	3,494*	591	803*
Net change in cash	(1,887)*	(2,395)*	(2,995)	(1,339)*	188*	5,271*	3,483	445*	(1,686)*	(486)*	(3,454)	(2,805)*

† Share count changed about 1/5 in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/32 in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Glucotrack	1,124	not reported	(3,616)*	10.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Aethlon Medical	4,934	not reported	(1,897)	711,136	2.6 quarters	Q1 FY27 10-QJun 30, 2026
Family Office of America	637	533	149*	30.8M	—	Q2 FY26 10-QJun 30, 2026
Odyssey Health	122	not reported	(160)*	110.2M	0.8 quarters	Q4 FY26 10-KJul 31, 2026
Autonomix Medical	3,460	0	(3,544)	971,043	1.0 quarters	Q1 FY27 10-QJun 30, 2026
Sonoma Pharmaceuticals	5,338	6,406	(649)	4.8M	8.2 quarters	Q1 FY27 10-QJun 30, 2026
Nuwellis	3,922	1,969	(3,175)*	3.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Adm Tronics Unlimited	223	not reported	(33)	67.6M	6.8 quarters	Q1 FY26 10-QJun 30, 2026
Bone Biologics	6,088	not reported	(532)*	3.4M	9.8 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.